Heart Attack
A heart attack, or acute myocardial infarction, occurs when blood flow to a part of the heart is blocked, causing damage to the heart muscle. This can lead to severe health complications and requires immediate medical attention.
Heart Attack Treatment: Evolocumab vs. Standard Care
We are studying whether the medication evolocumab can better prevent heart-related problems compared to standard treatments for patients who have recently had a heart attack. This trial focuses on improving cholesterol control and reducing hospitalizations.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you 55 years old or older?
- Do you have a history of heart problems like a heart attack or severe chest pain?
- Are you currently pregnant, breastfeeding, or planning to become pregnant?
- Are you taking any medications for cholesterol, like Lipitor (Atorvastatin) or Crestor (Rosuvastatin)?
- Do you have active cancer or severe liver disease?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Assistance Publique Hopitaux De Paris
Service de Cardiologie
Angers, France
Centre Hospitalier Universitaire D'Angers
Service de cardiologie
Angers, France
Centre Hospitalier D'Antibes Juan Les Pins
Service de Cardiologie, USIC
Antibes, France
Sponsor: Assistance Publique Hopitaux De Paris
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.